Pesquisar um ensaio clínico
Outras opções de pesquisa
7 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ESPANHA
Comunidad Valenciana
VALENCIA
APOLLO: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor - ES
Hospital Universitario Doctor Peset
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
PREDICT: Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM). Safety Study in a General Autologous Transplant Population (Phase III) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide (REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma ... - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase II Trial of Autologous Stem Cell Transplant in Multiple Myeloma Patients Following Conditioning with Intravenous Busulfan and Melphalan (terminated)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA
A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura - ES (Completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
ESPANHA
Comunidad Valenciana
VALENCIA